Articles On Resapp Health (ASX:RAP)

The ResApp Health Ltd (ASX: RAP) share price has returned from its trading halt and raced to a 52-week high this morning. At the time of writing the digital health company’s shares are up over 17% to a 52-week high of 29 cents. Why is the...

On Stockhead today: Tim Treadgold on why gold miner Pantoro is a stock to watch, milk stocks in healthier shape thanks to Bellamy’s, Barry FitzGerald talks Salt Lake Pot Ash in Explorer’s Podcast and just how much do neobanks scare the Big...

In afternoon trade the S&P/ASX 200 index is on course to start the week with a small gain. At the time of writing the benchmark index is up 0.15% to 6,726 points. Four shares that are climbing more than most today are listed below. Her...

30 Sep 2019 - ResApp (ASX:RAP) has flagged top-line results from its prospective, blinded at-home obstructive sleep apnoea study.

Digital health company ResApp Health (ASX: RAP) has updated the market with positive top-line results from its prospective, blinded at-home obstructive sleep apnoea study that included 308 patients. Sleep apnoea is a common sleep disorder w...

The ResApp Health Ltd (ASX: RAP) share price has started the week on a positive note. In morning trade the digital health company’s shares have surged 11% higher to 24.5 cents. This leaves the company’s shares trading within sight of their...

Shares in Bionomics (ASX:BNO) have flown to their highest point since May as it looks redo the failed post traumatic stress disorder trial that wiped out 66 per cent of the company’s value last October. Bionomics conducted a pharmacokinetic...

ResApp Health (ASX: RAP) has received Europe’s CE Mark approval for its latest smartphone-based respiratory disease diagnostic test for adults and children, paving the way for the company to sell the test throughout the region. CE Mark appr...

26 Sep 2019 - ResApp Health (ASX:RAP) has received CE Mark approval for ResAppDx-EU version 2, the latest version of the world’s first smartphone-based diagnostic test for respirat…

The notion of ‘everything old is new again’ applies not just to fickle fashion trends, but to drug development as well. Drug reformulations are all the rage and it’s not such a bad thing. Think of Paradigm Biopharmaceuticals (ASX:PAR) with...

3 Investing Mistakes I Made So You Don't Have To In 2016 I opened a trading account deposited $3,000 and bought shares in Resapp (ASX:RAP) and Fastbrick Robotics (ASX: FBR).  RAP & FBR were companies supposedly spearheading innovation...

ResApp Health Limited (ASX: RAP), is a prime healthcare company headquartered in Brisbane, Australia that creates clinically validated, regulatory-cleared, smartphone applications based digital tools to diagnose and manage acute respiratory...

The ResApp Health Ltd (ASX: RAP) share price has been a strong performer on the ASX on Friday. In late morning trade the digital health company’s shares have rocketed 30% higher to 19.5 cents. Why is the ResApp share price rocketing higher...

Digital health innovator ResApp Health (ASX: RAP) has received a significant boost courtesy of European regulatory approval for its first commercial product, ResAppDx-EU. The smartphone app has received CE Mark certification as a Class 2a m...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Analysts have lifted their recommendation for coughing app biotech ResApp (ASX:RAP) to a speculative buy ahead of a “critical” six months for the company. ResApp has sent its shareholders on a rollercoaster ride over the past couple of year...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Digital health company ResApp Health (ASX:RAP) has announced it has received $1.785 million from its R&D tax incentive claim for the financial year ending 30 June 2018.